Haemostatic Factors and Inhibitors and Coronary Artery Bypass Grafting: Preoperative Alterations and Relations to Graft Occlusion
Elisabeth Moor
1
The Department of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Anders Hamsten
1
The Department of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
5
The Department of Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Margareta Blombäck
3
The Departments of Clinical Chemistry and Blood Coagulation , King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Istvan Herzfeld
4
The Department of Thoracic Radiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Björn Wiman
3
The Departments of Clinical Chemistry and Blood Coagulation , King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Lars Rydén
1
The Department of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
Graft closure remains a major problem after coronary artery bypass surgery. While a number of graft characteristics influencing the risk of occlusion have been defined, the role of haemostatic factors and inhibitors has not been studied in detail. The present study examined the time course of changes in blood coagulation and fibrinolytic function after coronary artery bypass grafting in 20 consecutive patients. Pre- and postoperative determinations of haemostatic factors and inhibitors were also related to the presence of graft occlusion assessed by angiography at three months after surgery. A broad panel of haemostatic tests was used preoperatively, on the first, third and eight postoperative days, and at three months after surgery. A particular emphasis was placed on fibrinogen, factor VII activity, von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) activity, anticoagulant proteins C and S, thrombin-antithrombin complex and D-dimer. A marked activation of the coagulation cascade was noted postoperatively along with enhanced degradation of cross-linked fibrin. The degree of activation of blood coagulation and fibrinolysis differed widely between individuals and appeared to relate only partly to the acute phase reaction produced by the surgical trauma. Preoperative values of haemostatic factors and inhibitors showed fairly weak associations with the levels of postoperative determinations. Basal tPA and factor VIII levels, fibrinogen and TAT concentrations on the third and eighth postoperative day, and factor VII amidolytic activity on the third postoperative day differed (p <0.05) between patients with and without occluded grafts at reangiography. Accordingly, combined pre- and postoperative assessment of haemostatic function may contribute to the identification of individuals at risk for early graft closure after coronary artery bypass grafting.
References
1
Angelini GD,
Newby AC.
The future of saphenous vein asa coronary bypass conduit. Eur Heart J 1989; 10: 273-280
6
Sanz G,
Pajaron A,
Alegrfa E,
Coello I,
Cardona M,
Fournier JA,
Gomez-Recio M,
Ruano J,
Hidalgo R,
Medina A,
Oiler G,
Colman T,
Malpartida F,
Xavier B.
GESIC Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation 1990; 82: 765-773
7
Meade TW,
North WRS,
Chakrabarti R,
Stirling Y,
Haines AP,
Thompson SG.
Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i 1050-1054
8
Wilhelmsen L,
Svardsudd K,
Korsan-Bengtsen K,
Larsson B,
Welin L,
Tibblin G.
Fibrinogen as a risk factor forstroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
10
Meade TW,
Mellows S,
Brozovic M,
Miller GJ,
Chakrabarti RR,
North WRS,
Haines AP,
Stirling Y,
Imeson JD,
Thompson SG.
Haemostatic function and ischemic heart disease: principal resultsof the Northwick Park heart study. Lancet 1986; ii 533-537
11
Hamsten A,
Blomback M,
Wiman B,
Svensson J,
Szamosi A,
de Faire U,
Mettinger L.
Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66
12
Hamsten A,
Wiman B,
de Faire U,
Blomback M.
Increased plasma levels of a rapid inhibitor of tissue plasminogenactivator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
13
Hamsten A,
de Faire U,
Walldius G,
Dahlen G,
Szamosi A,
Landou C,
Blomback M,
Wiman B.
Plasminogen activator inhibitorin plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii 3-9
14
Meade TW.
The epidemiology of haemostaticand other variables in coronary artery disease. In: Thrombosis and Haemostasis.
Verstraete M,
Vermylen J,
Lijnen HR,
Arnout J.
(eds)
Leuven: International Society on Thrombosis and Haemostasis and Leuven University Press; 1987. pp 37-60
15
Lombardi R,
Mannucci PM,
Seghatchian MJ,
Vicente Garcia V,
Coppola R.
Alterations of factor VIII von Willebrand factor in clinical conditions associated with an increase in its plasma concentration. Br J Haematol 1981; 49: 61-68
20
Pelzer H,
Schwarz A,
Heimburger N.
Determination of human Thrombin-Antithrombin III complex in plasmawith an enzyme-linked immunosorbentassay. Thromb Haemost 1988; 59: 101-106
21
Malm J,
Laurell M,
Dahlback B.
Changes in the plasma levels ofvitamin Independent proteins C and S and of C4b-binding protein duringpregnancy and oral contraception. British J of Haematol 1988; 68: 437-443
22
Rylatt DB,
Blake AS,
Cottis LE,
Massingham DA,
Fltecher WA,
Masci PP,
Whitaker AN,
Elms M,
Bunce I,
Webber AJ,
Wyatt D,
Bundesen PG.
An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
23
Silveira AMV,
Yamamoto T,
Adamson L,
Hessel B,
Blomback B.
Application of an enzyme-linkedimmunosorbent assay (ELISA) to von Willebrand factor (vWF) and its deratives. Thromb Res 1986; 43: 91-102
27
Abildgaard U,
Lie M,
Odegard OR.
Antithrombin (heparin cofactor)assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
28
Vermylen C,
de Vreker RA,
Verstraete M.
A rapid enzymatic method for assay of fibrinogen fibrin polymerisation time (FPT test). Clin Chim Acta 1963; 8: 418-424
32
Beaumont JL,
Carlson LA,
Cooper GR,
Fejfar Z,
Fredrickson DS,
Strasser T.
Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970; 43: 891-915
33
Rakoczi I,
Chamone D,
Verstraete M,
Collen D.
The relevance of clinical and hemostasis parameters for the prediction of postoperative thrombosis ofthe deep veins of the lower extremity in gynecologic patients. Surgery, Gynecology and Obstetrics 1980; 151: 225-231
34
Modig J,
Borg T,
Bagge L,
Saldeen T.
Role of extradural and of general anaesthesia in fibrinolysis and coagulation after total hip surgery. Br J Anaesth 1983; 55: 625-629
35
Mellbring G,
Nilsson T,
Bergsdorf N,
Wallen P.
Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis. Thromb Res 1984 36. 331-334
36
Fredin H,
Nilsson B,
Rosberg B,
Tengborn L.
Pre- and postoperative levels of antithrombin III with special reference to thromboembolism after total hip replacement. Thromb Haemost 1983; 49: 158-161
37
Bredbacka S,
Andreen M,
Blomback M,
Wykman A.
Activation of cascade systems by hip arthroplasty. No difference between fixationwith and without cement. Acta Orthop Scand 1987 58. 231-235
38
Bergman A,
Andreen M,
Blomback M.
Plasma substitution with 3% dextran-60 in orthopaedic surgery: influence on plasma colloid osmotic pressure, coagulation parameters, immunoglobulins and other plasma constituents. Acta Anaestesiol Scand 1990; 34: 21-29
39
Jones DK,
Luddington R,
Higenbottam TW,
Scott J,
Cavarocchi N,
Reardon D,
Calvin J,
Wallwork J.
Changes in factor VIII proteinsafter cardiopulmonary bypass in mansuggests endothelial damage. Thromb Haemost 1988; 60: 199-204
41
Young J.
Coagulation abnormalities with cardiopulmonary bypass. In: Pathophysiology and techniques of cardiopulmonary bypass.
Uteley JR.
ed
London: Williams and Wilkins; 1982. 1 88-105
42
Arnesen H,
Semb G,
Hoi R,
Karlsen H.
Fibrinolytic capacity after venous stasis in patients undergoing aorto-coronary by-pass surgery. Relation to shunt occlusion. Scand J Haematol 1983 30. suppl 39 43-46
43
Miller GJ,
Seghatchian MJ,
Walter SJ,
Howarth DJ,
Thompson SG,
Esnouf MP,
Meade TW.
An association between the factor VII coagulant activity and thrombin activity induced by surface/cold exposure of normal human plasma. Br J Haematol 1986; 62: 379-384
46
Meade TW,
Vickers MV,
Thompson SG,
Seghatchian MJ.
The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-534
48
Gaffney PJ,
Lane DA,
Kakkar VV,
Brasher M.
Characterization of a soluble D-dimer E complex in cross linked fibrin digests. Thromb Res 1975; 7: 89-99
50
Wiman B,
Chmielewska J,
Ranby M.
Inactivation of tissue plasminogen activator in plasma: demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3647
